Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $93,007.67 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 623 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $149.29, for a total value of $93,007.67. Following the transaction, the insider now owns 3,442 shares of the company’s stock, valued at approximately $513,856.18. This represents a 15.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, December 31st, Ingrid Delaet sold 272 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20.
• On Tuesday, December 17th, Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.00, for a total value of $147,285.00.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $150.51 on Friday. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The company has a market cap of $15.24 billion, a P/E ratio of 40.35 and a beta of 0.33. The business has a fifty day moving average of $138.41 and a two-hundred day moving average of $131.64.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%. Sell-side analysts predict that Neurocrine Biosciences, Inc. will post 3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several research reports. Morgan Stanley increased their price target on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $190.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Raymond James reaffirmed an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $166.85.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NBIX. Golden State Wealth Management LLC acquired a new stake in Neurocrine Biosciences during the fourth quarter worth approximately $25,000. Brooklyn Investment Group lifted its stake in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 115 shares during the period. Blue Trust Inc. boosted its holdings in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Neurocrine Biosciences by 53.5% during the fourth quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock worth $51,000 after purchasing an additional 130 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at $61,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.